Eligible NHS patients missing out on new medicines that could extend lives and add £billions to the UK economy
New research by PwC for the ABPI published today sets out the potential benefits of increased investment in clinically- and cost-effective new medicines to patients, society, and the economy.
Read the full articleYou might also wanna read
Why the government must urgently raise the NICE cost-effectiveness threshold
ABPI·2d ago
Understanding NHS medicines spending in England
ABPI·2d ago
ABPI response to Life Sciences Competitiveness Indicators
ABPI·2d ago
Updates to the NHS Commercial Framework must deliver more flexibility to support timely access to medicines
ABPI·3d ago
Disclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to grow
ABPI·3d ago
Package deals in the pharmaceutical industry and Disclosure UK data
ABPI·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.